To assess through use of MRI, the efficacy and safety of intra-arterial and intravenous thrombolysis in acute ischemic stroke patients within 3-9 hours time window.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
Prospective, multi-center, randomized, open, assessor-blind study.
Patients in 3-6 hours time window receive intravenous or intravenous thrombolysis with rt-PA randomly. Patients in 6-9 hours time window receive intravenous thrombolysis or conventional therapy randomly. All enrolled patients have standardized DWI, PWI and MRA.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Reperfusion, assessed 24 to 48 hours post treatment and defined as either ?30% reduction of MTT volume of abnormality or ?2 points improvement on the TICI grading scheme using MRA.|
|Secondary||The combined analysis of the NIHSS, modified Rankin scale (mRS), and Barthel Index (BI) defined as?8 points improvement or scoring 0 to 1 on the NIHSS, a score of 0 to 2 on mRS, and a BI score of 75 to 100 at 90 days.|